Analysts forecast that CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) will post earnings of ($1.91) per share for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for CRISPR Therapeutics’ earnings, with estimates ranging from ($2.18) to ($1.65). CRISPR Therapeutics posted earnings per share of ($1.51) during the same quarter last year, which would indicate a negative year over year growth rate of 26.5%. The business is scheduled to issue its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that CRISPR Therapeutics will report full-year earnings of ($7.69) per share for the current year, with EPS estimates ranging from ($9.76) to ($3.03). For the next fiscal year, analysts forecast that the firm will report earnings of ($7.21) per share, with EPS estimates ranging from ($11.45) to ($3.21). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for CRISPR Therapeutics.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last released its earnings results on Monday, February 14th. The company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.10). CRISPR Therapeutics had a return on equity of 16.21% and a net margin of 41.28%. The business had revenue of $12.90 million during the quarter, compared to analysts’ expectations of $5.39 million.
Several institutional investors have recently added to or reduced their stakes in CRSP. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of CRISPR Therapeutics during the first quarter worth about $289,982,000. Nikko Asset Management Americas Inc. lifted its holdings in CRISPR Therapeutics by 31.3% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 4,319,471 shares of the company’s stock valued at $330,526,000 after acquiring an additional 1,029,955 shares during the period. Norges Bank acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $44,918,000. Renaissance Technologies LLC acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $43,865,000. Finally, Capital World Investors acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $31,940,000. 55.21% of the stock is owned by hedge funds and other institutional investors.
Shares of CRISPR Therapeutics stock opened at $49.62 on Friday. The firm has a market cap of $3.84 billion, a P/E ratio of 11.23 and a beta of 2.02. CRISPR Therapeutics has a 12 month low of $48.38 and a 12 month high of $169.76. The stock’s fifty day moving average price is $60.78 and its 200-day moving average price is $71.40.
About CRISPR Therapeutics (Get Rating)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.